INTERVIEW: Oxford BioDynamics Highly promising new approach ALS diagnosis

Oxford BioDynamics Plc (LON:OBD) CSO Dr Alexandre Akoulitchev explains to DirectorsTalk how the OBD work on ALS published in EBioMedicine fits into the bigger picture around this disease, the nature of the biomarkers and their relation to ALS, how quickly they could you predict ALS and the next plans for OBD technology in the ALS field.

Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    Insurance Data May Predict ALS, Research Shows

    A machine-learning model based on insurance information from amyotrophic lateral sclerosis (ALS) patients may be able to speed diagnosis of the disease in others, research suggests. The findings were presented at the 30th International Symposium on ALS/MND, in the

    Oxford BioDynamics

    ‘Jumping Genes’ Identified as Possible Cause of ALS

    A new study identified a group of sporadic amyotrophic lateral sclerosis (ALS) patients whose disease may arise from a group of “jumping genes” unleashed when TDP-43 protein accumulates in clumps in the brain and spinal cord. These “jumping genes” —

    Oxford BioDynamics

    Inflammatory processes may play role in ALS

    The cause of amyotrophic lateral sclerosis (ALS) — a disabling neurodegenerative disease that affects nerve cells in the brain and spinal cord and leads to weakened muscles and early death — is not fully understood, but

    Oxford BioDynamics

    Oxford Biodynamics Business

    Our proprietary technology platform enables pharmaceutical companies to accelerate and improve the rate of drug discovery and development Through the development of epigenetic biomarkers, EpiSwitch™ can help pharmaceutical companies to: REDUCE the risk, cost and time to market for therapeutic development programmes GAIN significant insights into

    Oxford BioDynamics

    EpiSwitch Technology

    EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”).  CCSs can provide a compelling, stable framework from which changes in the regulation of

    Oxford BioDynamics

    Exercise may help to slow Motor Neuron loss in ALS

    Exercise appears to benefit people with amyotrophic lateral sclerosis (ALS) by normalizing molecular changes that occur at the junction of nerves and muscles, but by degrees that depend on the type of exercise, a study in a mouse model of

    Oxford BioDynamics

    Oxford Biodynamics EpiSwitch featured in SITC’s 34th Annual Meeting

    Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers for the pharmaceutical and biotechnology industry, has announced that data yielded by application of its 3D genome architecture technology platform, EpiSwitch™,

    Oxford BioDynamics

    What is Motor Neurone Disease (ALS)?

    History  The NHS describes motor neurone disease (MND) as: ‘An uncommon condition that affects the brain and nerves. It causes weakness that gets worse over time.’ The weakness is caused by the deterioration of motor neurons,

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    It has been over 115 years since the Chromosome Theory of Inheritance, the proposal that chromosomes carried the factors of Mendelian inheritance, was articulated by Walter Sutton and Theodor Boveri. Since then, we have seen a

    Oxford BioDynamics

    A robust and reliable methodology for personalised medicine

    Oxford BioDynamics’ (OBD) EpiSwitchTM platform is the first industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs provide a robust, stable framework

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease